General information about DLBCL treatment and care for internists. Not meant for hematologist, though.
Sorry for lagging of explanation but what in the slide should be sufficient.
This presentation is about chronic lymphocytic leukemia (CLL), its epidemiology and incidence, staging, molecular characteristics, clinical features and management.
Immunotherapy for Metastatic Triple Negative Breast Cancerbkling
Sylvia Adams, MD, medical oncologist, and associate professor at the NYU School of Medicine, discusses the latest research including the role of immunology in the treatment of triple negative metastatic breast cancer. This webinar was hosted on October 19, 2016.
Audio and slides for this presentation are available on YouTube: http://youtu.be/ozNSEND5PbE
Erica Mayer, MD, MPH, of the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, discusses triple-negative breast cancer and what makes it different from other forms of breast cancer. Mayer also talks about treatment options for triple-negative breast cancer and what you need to know about clinical trials for the disease.
This presentation is about chronic lymphocytic leukemia (CLL), its epidemiology and incidence, staging, molecular characteristics, clinical features and management.
Immunotherapy for Metastatic Triple Negative Breast Cancerbkling
Sylvia Adams, MD, medical oncologist, and associate professor at the NYU School of Medicine, discusses the latest research including the role of immunology in the treatment of triple negative metastatic breast cancer. This webinar was hosted on October 19, 2016.
Audio and slides for this presentation are available on YouTube: http://youtu.be/ozNSEND5PbE
Erica Mayer, MD, MPH, of the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, discusses triple-negative breast cancer and what makes it different from other forms of breast cancer. Mayer also talks about treatment options for triple-negative breast cancer and what you need to know about clinical trials for the disease.
Lymphoma is the third most common cancer in children <15 years of age.The prognosis for children with newly diagnosed chemosensitive non-Hodgkin’s lymphoma (NHL) and Hodgkin’s disease (HD) has improved significantly.Despite the generally excellent prognosis of children and adolescents with Hodgkin’s lymphoma (HL), approximately 15% of patients relapse. Aggressive chemotherapy followed by autologous bone marrow transplantation has been used with some improvement in survival.
One of my best friends (when I was a teenager) died of leukemia. Several advances have been made in the ensuing decades (see attached document). Watch this space for additional notes.
Stem Cell Transplantation in Hodgkin’s Lymphoma Past, Present and FutureAmir Abbas Hedayati Asl
Treatment for HL has improved significantly since the ABVD chemotherapeutic combination was invented over 30 years ago .
Despite using the same ABVD regimen in most patients treated in the first line, we now have a much better understanding of disease biology and the late side effects of therapy, and we have moved toward a personalized, risk-adapted approach.
This approach promises to deliver low toxicities and high cure rates for lower risk patients while reserving aggressive regimens for those high risk patients who really need them.
For the minority of patients who fail first-line therapy, novel drugs like the antibody-drug conjugate BV and immunotherapies with nivolumab and pembrolizumab have produced high response rates and durability of benefit.
Further research is needed to determine whether these novel drugs could make life better for both patients with HL who are undergoing treatment and for the growing cohort of HL survivors.
diffuse large B cell lymphoma recent molecular classification
molecular classification and their time frame with references
Recent advantages of DLBCL and thier implication in therapy
A Strategic Approach: GenAI in EducationPeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
Safalta Digital marketing institute in Noida, provide complete applications that encompass a huge range of virtual advertising and marketing additives, which includes search engine optimization, virtual communication advertising, pay-per-click on marketing, content material advertising, internet analytics, and greater. These university courses are designed for students who possess a comprehensive understanding of virtual marketing strategies and attributes.Safalta Digital Marketing Institute in Noida is a first choice for young individuals or students who are looking to start their careers in the field of digital advertising. The institute gives specialized courses designed and certification.
for beginners, providing thorough training in areas such as SEO, digital communication marketing, and PPC training in Noida. After finishing the program, students receive the certifications recognised by top different universitie, setting a strong foundation for a successful career in digital marketing.
The French Revolution, which began in 1789, was a period of radical social and political upheaval in France. It marked the decline of absolute monarchies, the rise of secular and democratic republics, and the eventual rise of Napoleon Bonaparte. This revolutionary period is crucial in understanding the transition from feudalism to modernity in Europe.
For more information, visit-www.vavaclasses.com
Honest Reviews of Tim Han LMA Course Program.pptxtimhan337
Personal development courses are widely available today, with each one promising life-changing outcomes. Tim Han’s Life Mastery Achievers (LMA) Course has drawn a lot of interest. In addition to offering my frank assessment of Success Insider’s LMA Course, this piece examines the course’s effects via a variety of Tim Han LMA course reviews and Success Insider comments.
Synthetic Fiber Construction in lab .pptxPavel ( NSTU)
Synthetic fiber production is a fascinating and complex field that blends chemistry, engineering, and environmental science. By understanding these aspects, students can gain a comprehensive view of synthetic fiber production, its impact on society and the environment, and the potential for future innovations. Synthetic fibers play a crucial role in modern society, impacting various aspects of daily life, industry, and the environment. ynthetic fibers are integral to modern life, offering a range of benefits from cost-effectiveness and versatility to innovative applications and performance characteristics. While they pose environmental challenges, ongoing research and development aim to create more sustainable and eco-friendly alternatives. Understanding the importance of synthetic fibers helps in appreciating their role in the economy, industry, and daily life, while also emphasizing the need for sustainable practices and innovation.
2024.06.01 Introducing a competency framework for languag learning materials ...Sandy Millin
http://sandymillin.wordpress.com/iateflwebinar2024
Published classroom materials form the basis of syllabuses, drive teacher professional development, and have a potentially huge influence on learners, teachers and education systems. All teachers also create their own materials, whether a few sentences on a blackboard, a highly-structured fully-realised online course, or anything in between. Despite this, the knowledge and skills needed to create effective language learning materials are rarely part of teacher training, and are mostly learnt by trial and error.
Knowledge and skills frameworks, generally called competency frameworks, for ELT teachers, trainers and managers have existed for a few years now. However, until I created one for my MA dissertation, there wasn’t one drawing together what we need to know and do to be able to effectively produce language learning materials.
This webinar will introduce you to my framework, highlighting the key competencies I identified from my research. It will also show how anybody involved in language teaching (any language, not just English!), teacher training, managing schools or developing language learning materials can benefit from using the framework.
5. Diffuse large B cell lymphoma
The most common subtype of
non-Hodgkin lymphoma
Medium-to-large size B cell malignancy
grows in diffuse pattern
6. Diffuse large B cell lymphoma
The most common subtype of
non-Hodgkin lymphoma
Medium-to-large size B cell malignancy
grows in diffuse pattern
When can not be put into predefined
category we call DLBCL,NOS
7. Simplified version of DLBCL subgroup
GCB
Non-GCB
PMBCL
Primary CNS
DLBCL
High grade
DLBCL
AIDS-related
DLBCL
8. Immunophenotype
Positive for CD45 (leukocyte common
antigen)
→ not positive in erythroid, plasma cell, or
other tumors
Positive for B cell marker
CD19, CD20, CD22, CD79a, PAX5
Negative for T cell marker
CD3, CD4, CD8
10. Immunophenotype
Ki67 → indicate proliferation rate (40-90% or more)
MYC and BCL2 co-expression (double expresser) had a poorer prognosis
→ This is not equal to double hit lymphoma
11. AIDS-related DLBCL
Associated with very low CD4+
count (eg. < 50/mL)
The prognosis is improved with concurrent ART
CNS prophylaxis is recommended in all cases
If CD4+
count < 50/mL rituximab should be defer unit CD4+
improved
Plasmablastic
lymphoma
Primary
Effusion
lymphoma
Primary
CNS
lymphoma
Burkitt
lymphoma
12. Primary mediastinal large B cell lymphoma
Disease involve primarily in mediastinum
Typically occur in young female patients
Has feature overlapping with Hodgkin lymphoma
IHC - similar to DLBCL with CD30+
weakly, CD15-
, Bcl6+
Tumor cell has decreased MHC I, II expression and increased PD-ligand
R-CHOP with RT or DA-EPOCH-R
13. Primary CNS large B cell lymphoma
One of AIDS defining lymphoma
Treatment involve high dose of blood brain barrier penetrating chemotherapy
HD-MTX
HD-AraC
Radiation can be used with palliative intention
Associated with dementia in elderly (> 60 y)
14. High-grade DLBCL
Appeared as Burkitt-like DLBCL
Medium to large monotonous cells
Or blastoid appearance
May have starry sky macrophage
Have rearrangement of MYC and BCL2 and/or BCL6 (double hit, triple hit)
If no such rearrangement → HG-BL, NOS
15. Clinical feature
Progressive onset of lymph node enlargement
Extranodal involvement as frequent as 40%
Common site: GI tract, Waldeyer ring, testes, marrow, etc
May have B-symptoms
16. Staging of lymphoma
A → asymptomatic
B → B symptom
Weight loss > 10%
Fever
Night sweat
E → extranodal involvement
X → bulky disease (> 8-10 cm)
17. Prognosis
International prognostic index (IPI) score
Developed from pooled data of lymphoma but major population consist of DLBCL
Age > 60 years
Performance status ECOG > 2
LDH > normal range
Extranodal site > 1
Stage II-IV
21. Treatment of DLBCL
Pretreatment evaluation
Immunochemotherapy
R-CHOP
Salvage treatment
3-4 cycles of
chemotherapy
2-4 cycles
more
Assess for response
CT, BMA, PET/CT
22. Treatment of DLBCL
Pretreatment evaluation
Immunochemotherapy
R-CHOP
Salvage treatment
Cardiac function
Performance status
- HIV
- Hepatitis B
Comorbidity
25. Follow up after treatment
After patient achieved CR F/U every 1-2 months
After 2 years incidence of relapse is low; F/U every 6-12 months
Late relapse may occur after 8 years and can retreat with the same regimen
Keep vaccination on schedule after 12 months of treatment
27. Rituximab efficacy vs chemo alone
Age Treatment Study outcome Long term outcome
GELA
LNH-98.5
60-80 y 8R-CHOP vs 8CHOP 2y EFS 57 vs 38%
10y PFS 36.5 vs 20%
10y OS 43.5 vs 27.6%
MInT 18-60 y 6R-CHOP-like vs 6CHOP 3y EFS 79 v s 59%
6y EFS 74.3 vs 55.8%
6y PFS 80.2 vs 63.9%
6y OS 90.1 vs 80%
N Engl J Med 2002;346:235-42. Blood 2010 116:2040-5.
Lancet Oncol. 2006 May;7(5):379-91. Lancet Oncol. 2011 Oct;12(11):1013-22
28. Adverse events of rituximab
Infusion reaction
Reactivation of hepatitis B virus
Rituximab-induced pneumonitis
Progressive multifocal leukoencephalopathy (PML)
Humoral immune suppression
29. Infusion reaction of rituximab
Patients may experience rash, urticaria, angioedema, bronchospasm, fever, chills
Onset 30-120 min after infusion
Should be closely monitored in the 1st
cycle
Premedication with paracetamol, antihistamine, steroid
After reaction resolve rituximab can be reinitiate at 50% infusion rate
30. Patient at risk: HBsAg +ve, HBcAb IgG +ve
Chemotherapeutic regimens
Low risk: Azathioprine, methotrexate
Moderate risk: CHOP, fludarabine, high dose steroid (pred > 20 mg)
High risk: rituximab therapy ~ 5X risk
Prevention with entecavir, lamivudine up to 12 months after treatment with
surveillance
Reactivation of HBV
J Clin Transl Hepatol. 2016;4(2):143–50.
31. Lamivudine vs entecavir
Newly diagnosed DLBCL enter the clinical trial of R-CHOP 21 vs R-CHOP 14
HBsAg positive and HBV DNA < 103
copy/mL
Entecavir 0.5 mg vs lamivudine 100 mg
Primary endpoint: incidence of HBV related hepatitis
Secondary endpoint: HBV reactivation, chemo disruption
R-CHOP 21 or R-CHOP 14
1 week before and 6 months after treatment
JAMA. 2014;312(23):2521-30.
33. Rituximab-induced interstitial pneumonitis
Rare but potentially fatal complication
Present with dyspnea, fever, cough
HRCT chest reveal diffuse interstitial
pattern
PFT had restrict pattern
Incidence after the 4th cycle of rituximab
Treatment include systemic steroid
34. Rituximab-induced interstitial pneumonitis
In one retrospective review of 560
patients receiving R-Chemo or Chemo
329 patients received rituximab
Incidence of ILD was 3.95% (13/329)
4 patients had symptomatic disease
Leukemia & Lymphoma. 2015;56(6):1659–64.
35. Progressive multifocal leukoencephalopathy
Cause by JC virus in immunocompromised
patients
Present with subacute onset of focal neuro
deficit
Incidence was very low but fatal
In one report incidence was 2.89
case/1,000 patient-years
Blood 2009 114:3675;[abstract 3675]
41. Conclusion
DLBCL is the most common aggressive lymphoma
Common subtype DLBCL-NOS, PMBCL, primary CNS, AIDS-related lymphoma
The mainstay of therapy is R-chemo for CD20+
disease
Long term care for lymphoma survival
Disease surveillance
Vaccination